BioSpace News Archive

BIOASIS TECHNOLOGIES INC. announced that it has applied for approval from the TSX Venture Exchange to extend the expiry date of 5,797,795 common share purchase warrants issued to subscribers pursuant to the private placement of units which closed on April 11, 2017.

New Cleaner Protects Coated Lenses and Ensures Long-Lasting Comfort, as Well as Resistance to Deposits and Fogging

On March 19, the U.S. Food and Drug Administration approved Brexanolone, the first treatment indicated specifically for postpartum depression.

Turning Point Therapeutics, Inc., a clinical-stage precision oncology company designing and developing novel drugs to address treatment resistance, announced today the appointment of Jim Mazzola to lead corporate communication and investor relations, reporting to Chief Executive Officer Athena Countouriotis, M.D.

ClearCare, Inc. today announced general availability of its Quality of Care module, further empowering home care agencies to improve outcomes and lower health care spending by monitoring, reporting, and preventing serious complications among patients with chronic conditions.

CIRCULOGENE, advancing precision medicine through personalized molecular genetics testing, will be presenting three abstracts at the 2019 American Association for Cancer Research (AACR) Annual Meeting, March 29 - April 3, 2019, at the Georgia World Congress Center in Atlanta.

Riverside Partners, a Boston-based private equity firm, is introducing Revecore, a company bringing together best-in-class organizations to deliver specialized services in the most challenging areas of hospital revenue cycle management.

Republicans having reneged on their campaign promises to repeal the Affordable Care Act (ACA), while ACA has failed to deliver on its promise of affordable care to all, what comes next

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, today announced the appointment of Amit D. Munshi as Non-Executive Chairman of the Board of Directors.

VolitionRx Limited announced that its Executive Vice President, Investor Relations, Scott Powell, is scheduled to present at three conferences in March and April 2019.